Molecular Cancer Therapeutics

ISSNs: 1535-7163

Additional searchable ISSN (electronic): 1538-8514

American Association for Cancer Research Inc.

Scopus rating (2023): CiteScore 11.2 SJR 2.27 SNIP 1.016

Journal

Titles	Molecular Cancer Therapeutics Molecular cancer therapeutics
Additional searchable titles	Molecular cancer therapeutics, Molecular cancer therapeutics.
ISSNs	1535-7163
Additional searchable ISSN (electronic)	1538-8514
Publisher	American Association for Cancer Research Inc.
ZDB-ID	2063563-1
ZDB-ID	2062135-8

Keywords

ASJC Scopus subject areas

Oncology
Cancer Research

Library keywords

570 Biology
610 Medicine and health

The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models.

Handle, F., Puhr, M., Schaefer, G., Lorito, N., Hoefer, J., Gruber, M., Guggenberger, F., & 6 othersSanter, FR., Marques, RB., van, W. WM., Claessens, F., Erb, HHH. & Culig, Z., Sept 2018, In: Molecular cancer therapeutics.

Research output: Contribution to journal › Research article › Contributed › peer-review

Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization

Hinrichs, C. N., Ingargiola, M., Käubler, T., Löck, S., Temme, A., Köhn-Luque, A., Deutsch, A., & 3 othersVovk, O., Stasyk, O. & Kunz-Schughart, L. A., Feb 2018, In: Molecular Cancer Therapeutics. 17, 2, p. 393-406 14 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor

Zeng, S., Seifert, A. M., Zhang, J. Q., Cavnar, M. J., Kim, T. S., Balachandran, V. P., Santamaria-Barria, J. A., & 10 othersCohen, N. A., Beckman, M. J., Medina, B. D., Rossi, F., Crawley, M. H., Loo, J. K., Maltbaek, J. H., Besmer, P., Antonescu, C. R. & DeMatteo, R. P., Sept 2017, In: Molecular cancer therapeutics. 16, 9, p. 1954-1966 13 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines

Santer, F. R., Höschele, P. P. S., Su, J. O., Erb, H. H. H., Bouchal, J., Cavarretta, I. T., Parson, W., & 3 othersMeyers, D. J., Cole, P. A. & Culig, Z., Sept 2011, In: Molecular cancer therapeutics. 10, 9, p. 1644–1655

Research output: Contribution to journal › Research article › Contributed › peer-review

View all research output (4)

Research Portal of the TU Dresden

Molecular Cancer Therapeutics

Keywords

ASJC Scopus subject areas

Library keywords

Related content

The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models.

Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization

Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor

Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines